Unknown

Dataset Information

0

A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes.


ABSTRACT:

Background

Comorbidity has an adverse impact on cancer survival partly through its negative impact on receipt of curative treatment. Comorbidity is unevenly distributed within populations, with some ethnic and socioeconomic groups having considerably higher burden. The aim of this study was to investigate the inter-relationships between comorbidity, ethnicity, receipt of treatment, and cancer survival among patients with stomach and liver cancer in New Zealand.

Methods

Using the New Zealand Cancer Registry, M?ori patients diagnosed with stomach and liver cancers were identified (n?=?269), and compared with a randomly selected group of non-M?ori patients (n?=?255). Clinical and outcome data were collected from medical records, and the administrative hospitalisation and mortality databases. Logistic and Cox regression modelling with multivariable adjustment were used to examine the impacts of ethnicity and comorbidity on receipt of treatment, and the impact of these variables on all-cause and cancer specific survival.

Results

More than 70% of patients had died by two years post-diagnosis. As comorbidity burden increased among those with Stage I-III disease, the likelihood that the patient would receive curative surgery decreased (e.g. C3 Index score 6 vs 0, adjusted OR: 0.32, 95% CI 0.13-0.78) and risk of mortality increased (e.g. C3 Index score 6 vs 0, adjusted all-cause HR: 1.44, 95% CI 0.93-2.23). Receipt of curative surgery reduced this excess mortality, in some cases substantially; but the extent to which this occurred varied by level of comorbidity. M?ori patients had somewhat higher levels of comorbidity (34% in highest comorbidity category compared with 23% for non-M?ori) and poorer survival that was not explained by age, sex, site, stage, comorbidity or receipt of curative surgery (adjusted cancer-specific HR: 1.36, 95% CI 0.97-1.90; adjusted all-cause HR: 1.33, 95% CI 0.97-1.82). Access to healthcare factors accounted for 25-36% of this survival difference.

Conclusions

Patients with comorbidity were substantially less likely to receive curative surgery and more likely to die than those without comorbidity. Receipt of curative surgery markedly reduced their excess mortality. Despite no discernible difference in likelihood of curative treatment receipt, M?ori remained more likely to die than non-M?ori even after adjusting for confounding and mediating variables.

SUBMITTER: Sarfati D 

PROVIDER: S-EPMC4233029 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A retrospective cohort study of patients with stomach and liver cancers: the impact of comorbidity and ethnicity on cancer care and outcomes.

Sarfati Diana D   Gurney Jason J   Stanley James J   Koea Jonathan J  

BMC cancer 20141107


<h4>Background</h4>Comorbidity has an adverse impact on cancer survival partly through its negative impact on receipt of curative treatment. Comorbidity is unevenly distributed within populations, with some ethnic and socioeconomic groups having considerably higher burden. The aim of this study was to investigate the inter-relationships between comorbidity, ethnicity, receipt of treatment, and cancer survival among patients with stomach and liver cancer in New Zealand.<h4>Methods</h4>Using the N  ...[more]

Similar Datasets

| S-EPMC6397033 | biostudies-literature
| S-EPMC10401215 | biostudies-literature
| S-EPMC5534363 | biostudies-other
| S-EPMC10863540 | biostudies-literature
| S-EPMC7456957 | biostudies-literature
| S-EPMC9096912 | biostudies-literature
| S-EPMC9468675 | biostudies-literature
| S-EPMC5540631 | biostudies-other
| S-EPMC11019992 | biostudies-literature
| S-EPMC3855607 | biostudies-literature